Unraveling mutations in ribosomal proteins linked to cancer: Advancements in the understanding of cancer and ribosome function
By
Mirsada Čaušević
Robbie Loewith
Siniša Volarević
September 25, 2026
Clinical Scorecard: Unraveling mutations in ribosomal proteins linked to cancer: Advancements in the understanding of cancer and ribosome function
At a Glance
Category Detail
Condition Ribosomal protein mutations and associated cancers
Key Mechanisms Alterations in ribosomal composition and function affecting translation and cellular stress responses
Target Population Patients with ribosomopathies and hematopoietic malignancies
Care Setting Oncology and hematology
Key Highlights
Ribosomal proteins (RPs) are critical for ribosome function and cellular growth. Heterozygous loss-of-function RP mutations are linked to ribosomopathies and increased cancer susceptibility. Mutations in RPS15 and RPL10 are associated with chronic lymphocytic leukemia and other malignancies. Cancer-associated RP mutations may produce specialized ribosomes with altered translational properties. RiboCancer provides a systematic repository for studying RP mutations in cancer.
Guideline-Based Recommendations
Diagnosis
Consider genetic testing for RP mutations in patients with hematologic malignancies.
Management
Monitor for signs of ribosomopathy in patients with known RP mutations.
Monitoring & Follow-up
Assess translational efficiency and ribosomal function in patients with RP mutations.
Risks
Increased susceptibility to malignancies, particularly myeloid neoplasms.
Patient & Prescribing Data
Individuals with ribosomopathies and those at risk for malignancies due to RP mutations.
Targeted therapies may be necessary for managing malignancies associated with RP mutations.
Clinical Best Practices
Utilize CRISPR-engineered models to study the functional effects of RP mutations. Incorporate ribosome profiling and cryo-EM in research to understand translational changes.
Related Resources & Content